# Branched-chain amino acids and insulin resistance in type 2 diabetes: from metabolic dysregulation to therapeutic targets

**Authors:** Jie Mei, Fu-yuan Yang, Quan Gong

PMC · DOI: 10.3389/fendo.2025.1643231 · 2026-02-02

## TL;DR

This review explores how branched-chain amino acids contribute to insulin resistance in type 2 diabetes and discusses potential therapeutic strategies.

## Contribution

The paper provides a comprehensive overview of BCAAs' role in T2DM and highlights novel therapeutic approaches targeting their metabolism.

## Key findings

- Elevated BCAAs levels in T2DM patients are linked to impaired catabolic enzyme activity.
- BCAAs activate mTOR signaling, reducing insulin receptor sensitivity.
- Altered BCAAs metabolism is associated with gut microbiota changes that worsen insulin resistance.

## Abstract

Branched-chain amino acids (BCAAs) are a class of amino acids characterized by a branched aliphatic side chain, and they play critical physiological roles in humans, including protein synthesis, metabolic regulation, and immune system maintenance. Beyond serving as fundamental building blocks for protein biosynthesis, BCAAs and their metabolites also function as signaling molecules that regulate a variety of physiological processes, notably insulin secretion. Accumulating evidence indicates that plasma BCAAs levels are markedly elevated in patients with type 2 diabetes (T2DM), a phenomenon that may result from impaired activity of key enzymes in the BCAAs catabolic pathway, leading to metabolic dysregulation. It is widely recognized that BCAAs can activate the mTOR signaling cascade, thereby affecting insulin receptor sensitivity. In addition, aberrant BCAAs metabolism has been closely linked to alterations in the gut microbiota, which may further aggravate insulin resistance (IR). Taken together, dysregulated BCAAs metabolism may represent a critical mechanism underlying IR in T2DM. Therefore, this review summarizes current knowledge on BCAAs metabolism, explores its potential roles in the pathogenesis of IR in T2DM, and highlights emerging therapeutic strategies to reduce IR by targeting BCAAs metabolism.

## Linked entities

- **Chemicals:** branched-chain amino acids (PubChem CID 9886134)
- **Diseases:** type 2 diabetes (MONDO:0005148), T2DM (MONDO:0005148)

## Full-text entities

- **Genes:** MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}
- **Diseases:** IR (MESH:D007333), type 2 diabetes (MESH:D003924), metabolic (MESH:D008659)
- **Chemicals:** amino acids (MESH:D000596), BCAAs (MESH:D000597)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12907165/full.md

---
Source: https://tomesphere.com/paper/PMC12907165